Showing 6301-6310 of 8473 results for "".
- Biologics May Reduce Plaque Buildup in Psoriasis Patients' Arterieshttps://practicaldermatology.com/news/biologics-may-reduce-plaque-buildup-in-psoriasis-patients-arteries/2459913/Treating psoriasis with biologic drugs can reduce the early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke, according to a study funded by the Natio
- Jeuveau from Evolus Now FDA Cleared for Aesthetic Injectionhttps://practicaldermatology.com/news/jeuveau-from-evolus-now-fda-cleared-for-aesthetic-injection/2459914/The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. It will be available to physicians this sp
- New Data Show Cosentyx Improves Quality of Life in Patients Being Treated for Psoriasishttps://practicaldermatology.com/news/new-data-show-cosentyx-improves-quality-of-life-in-patients-being-treated-for-psoriasis/2459924/Novartis shared results from a pooled analysis of four Phase 3 clinical trials demonstrating patients with moderate to severe plaque psoriasis (PsO) treated with Cosentyx (secukinumab) 300mg reported improvements in mobility, self-care, and usual activities components of the EQ-5D-3L questionnair
- Dermatologists Prescribe the Most Antibiotics, But Usage Is Changinghttps://practicaldermatology.com/news/dermatologists-prescribe-the-most-antibiotics-but-usage-is-changing/2459935/The use of antibiotics to treat inflammatory skin conditions like acne and rosacea is decreasing over time, but there has been an increase in prescriptions associated with dermatologic surgical procedures, a new study finds. The study appears in
- Suneva Grows Their Aesthetics Portfolio with New Dealshttps://practicaldermatology.com/news/suneva-grows-their-aesthetics-portfolio-with-new-deals/2459946/Suneva® Medical, Inc., is partnering with Healeon Medical, Inc and Puregraft, LLC to add two new products to their a
- Dermavant Sciences Appoints Dr. Philip M. Brown as Chief Medical Officerhttps://practicaldermatology.com/news/dermavant-sciences-appoints-dr-philip-m-brown-as-chief-medical-officer/2459949/Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, appointed Philip M. Brown, MD, JD, as Chief Medical Officer. With more than 25 years of experience leading clinical development programs, Dr. Brown most recently served as head of global pharmaceutical drug development at G
- Modernizing Medicine Introduces New Patient Engagement Toolshttps://practicaldermatology.com/news/modernizing-medicine-introduces-new-patient-engagement-tools/2459951/Modernizing Medicine has launched enhanced patient engagement tools powered by Relatient that are designed to reduce no-shows and improve patient compliance, satisfaction, and operational efficiency. Patients who do not show for appointments can be a significant cost and ef
- National Rosacea Society: New Grants Available in 2019https://practicaldermatology.com/news/national-rosacea-society-new-grants-available-in-2019/2457536/The National Rosacea Society (NRS) has new grants available in 2019 to support research into potential causes and other key aspects of rosacea that may lead to improvements in its management, prevention, or potential cure. The deadline for submitting proposals for research grants in 2019 is
- EWG VERIFIED Goes Mainstream with Herbal Essences Shampooshttps://practicaldermatology.com/news/ewg-verified-goes-mainstream-with-herbal-essences-shampoos/2457544/
- Almirall and X-Chem Team Up to Develop Oral Compounds for Dermatological Diseaseshttps://practicaldermatology.com/news/almirall-and-x-chem-team-up-to-develop-oral-compounds-for-dermatological-diseases/2457545/Almirall, S.A. signed a collaborative research and license agreement with the X-Chem, Inc. for the development of oral compounds for patients suffering from dermatological diseases, a strategic area for Almirall. X-Chem, Inc. is a privately held biotechnology company focused on applying its indus